Celcuity (CELC) Long-Term Investments (2017 - 2018)

Celcuity (CELC) reported Long-Term Investments of $3.9 million for Q3 2018, down 43.59% quarter-over-quarter from $6.9 million in Q2 2018.

Celcuity (CELC) Long-Term Investments (2017 - 2018) Analysis & Trends

Celcuity has reported Long-Term Investments for 2 years, with the latest figure at $3.9 million in Q3 2018.

For the quarter ending Q3 2018, Long-Term Investments changed N/A year-over-year to $3.9 million; the trailing twelve-month figure through Sep 2018 stood at $3.9 million (changed N/A YoY), and the FY2017 full-year result was $7.2 million, changed N/A from the prior year.
Long-Term Investments for Q3 2018 stood at $3.9 million, down from $6.9 million in the prior quarter.
The five-year high for Long-Term Investments was $7.2 million in Q4 2017, with the low at $3.9 million in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	5.75 Bn
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Celcuity	4.14 Bn	3.42 Bn	-	-

Download Data